ALDX
Price
$4.86
Change
-$0.05 (-1.02%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
292.39M
113 days until earnings call
Intraday BUY SELL Signals
CANF
Price
$0.32
Change
-$0.06 (-15.79%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
15.74M
Intraday BUY SELL Signals
Interact to see
Advertisement

ALDX vs CANF

Header iconALDX vs CANF Comparison
Open Charts ALDX vs CANFBanner chart's image
Aldeyra Therapeutics
Price$4.86
Change-$0.05 (-1.02%)
Volume$14.23K
Capitalization292.39M
Can-Fite BioPharma
Price$0.32
Change-$0.06 (-15.79%)
Volume$2.49K
Capitalization15.74M
ALDX vs CANF Comparison Chart in %
ALDX
Daily Signal:
Gain/Loss:
CANF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALDX vs. CANF commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALDX is a Hold and CANF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ALDX: $4.91 vs. CANF: $0.38)
Brand notoriety: ALDX and CANF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALDX: 85% vs. CANF: 4570%
Market capitalization -- ALDX: $292.39M vs. CANF: $15.74M
ALDX [@Biotechnology] is valued at $292.39M. CANF’s [@Biotechnology] market capitalization is $15.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALDX’s FA Score shows that 0 FA rating(s) are green whileCANF’s FA Score has 1 green FA rating(s).

  • ALDX’s FA Score: 0 green, 5 red.
  • CANF’s FA Score: 1 green, 4 red.
According to our system of comparison, ALDX is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALDX’s TA Score shows that 1 TA indicator(s) are bullish while CANF’s TA Score has 4 bullish TA indicator(s).

  • ALDX’s TA Score: 1 bullish, 7 bearish.
  • CANF’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, CANF is a better buy in the short-term than ALDX.

Price Growth

ALDX (@Biotechnology) experienced а -6.12% price change this week, while CANF (@Biotechnology) price change was -3.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

ALDX is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALDX($292M) has a higher market cap than CANF($15.7M). ALDX YTD gains are higher at: -1.603 vs. CANF (-76.609). CANF has higher annual earnings (EBITDA): -8.91M vs. ALDX (-48.46M). ALDX has more cash in the bank: 81.9M vs. CANF (6.46M). CANF has less debt than ALDX: CANF (90K) vs ALDX (15.6M). CANF has higher revenues than ALDX: CANF (560K) vs ALDX (0).
ALDXCANFALDX / CANF
Capitalization292M15.7M1,860%
EBITDA-48.46M-8.91M544%
Gain YTD-1.603-76.6092%
P/E RatioN/AN/A-
Revenue0560K-
Total Cash81.9M6.46M1,269%
Total Debt15.6M90K17,333%
FUNDAMENTALS RATINGS
ALDX vs CANF: Fundamental Ratings
ALDX
CANF
OUTLOOK RATING
1..100
8198
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4295
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (18) in the Biotechnology industry is in the same range as ALDX (40). This means that CANF’s stock grew similarly to ALDX’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALDX (100). This means that CANF’s stock grew similarly to ALDX’s over the last 12 months.

ALDX's SMR Rating (96) in the Biotechnology industry is in the same range as CANF (100). This means that ALDX’s stock grew similarly to CANF’s over the last 12 months.

ALDX's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for CANF (95). This means that ALDX’s stock grew somewhat faster than CANF’s over the last 12 months.

ALDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CANF (100). This means that ALDX’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALDXCANF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
66%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ALDX
Daily Signal:
Gain/Loss:
CANF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RADLY4.410.16
+3.76%
Raia Drogasil SA
MZHOF33.80N/A
N/A
Mizuho Financial Group Inc.
TCNB6.05N/A
N/A
Town Center Bank (IL)
BKUTK501.00N/A
N/A
Bank of Utica (NY)
YNNHF1.70N/A
N/A
Yihai Intl Hldg Ltd.